Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, will present at the upcoming Wedbush PacGrow Healthcare Virtual Conference on Surfaces lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surfaces emerging preclinical pipeline, including SRF813 (targeting CD112R, also known as PVRIG).